Literature DB >> 11165091

Solubilization of rapamycin.

P Simamora1, J M Alvarez, S H Yalkowsky.   

Abstract

The solubilization of rapamycin, a poorly water soluble investigational immunosuppressive drug, by facilitated hydrotropy is presented. Partially water-miscible aromatic solutes (such as benzyl alcohol, benzoate, or benzoic acid) can be solubilized by water-miscible cosolvents, such as ethanol and propylene glycol. Once solubilized, the partially miscible aromatic solute becomes a solubilizing agent. This technique yielded a dramatic (>1000-fold) increase in the aqueous solubility of rapamycin.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11165091     DOI： 10.1016/s0378-5173(00)00617-7

Source DB:  PubMed          Journal:  Int J Pharm        ISSN： 0378-5173            Impact factor:   5.875


  49 in total

1.  A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs.

Authors:  Ho-Chul Shin; Adam W G Alani; Hyunah Cho; Younsoo Bae; Jill M Kolesar; Glen S Kwon
Journal:  Mol Pharm       Date:  2011-06-23       Impact factor: 4.939

2.  Continuous administration of the mTORC1 inhibitor everolimus induces tolerance and decreases autophagy in mice.

Authors:  Ammar Kurdi; Mireille De Doncker; Arthur Leloup; Hugo Neels; Jean-Pierre Timmermans; Katrien Lemmens; Sandra Apers; Guido R Y De Meyer; Wim Martinet
Journal:  Br J Pharmacol       Date:  2016-10-23       Impact factor: 8.739

3.  Molecular Targeting of Immunosuppressants Using a Bifunctional Elastin-Like Polypeptide.

Authors:  Yaping Ju; Hao Guo; Frances Yarber; Maria C Edman; Santosh Peddi; Srikanth Reddy Janga; J Andrew MacKay; Sarah F Hamm-Alvarez
Journal:  Bioconjug Chem       Date:  2019-08-23       Impact factor: 4.774

4.  Electrospun rapamycin-eluting polyurethane fibers for vascular grafts.

Authors:  Jingjia Han; Shady Farah; Abraham J Domb; Peter I Lelkes
Journal:  Pharm Res       Date:  2013-04-09       Impact factor: 4.200

5.  Epothilone B-based 3-in-1 polymeric micelle for anticancer drug therapy.

Authors:  Dae Hwan Shin; Glen S Kwon
Journal:  Int J Pharm       Date:  2017-01-03       Impact factor: 5.875

6.  Preformulation Studies of a Liposomal Formulation Containing Sirolimus for the Treatment of Dry Eye Disease.

Authors:  Mónica Anayántzin Linares-Alba; Magda Berenice Gómez-Guajardo; Joice Furtado Fonzar; Dennis E Brooks; Gustavo Adolfo García-Sánchez; Maria Josefa Bernad-Bernad
Journal:  J Ocul Pharmacol Ther       Date:  2015-10-15       Impact factor: 2.671

7.  Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbits' eyes.

Authors:  Mayara Rodrigues Brandão De Paiva; Nayara Almeida Lage; Maria Carolina Andrade Guerra; Marcos Paulo Gomes Mol; Marcela Coelho Silva Ribeiro; Gustavo De Oliveira Fulgêncio; Dawidson A Gomes; Isabela Da Costa César; Sílvia Ligório Fialho; Armando Silva-Cunha
Journal:  Doc Ophthalmol       Date:  2018-11-19       Impact factor: 2.379

Review 8.  Nanomedicines in renal transplant rejection--focus on sirolimus.

Authors:  Li-Jiuan Shen; Fe-Lin Lin Wu
Journal:  Int J Nanomedicine       Date:  2007

9.  Elastin-based protein polymer nanoparticles carrying drug at both corona and core suppress tumor growth in vivo.

Authors:  Pu Shi; Suhaas Aluri; Yi-An Lin; Mihir Shah; Maria Edman; Jugal Dhandhukia; Honggang Cui; J Andrew MacKay
Journal:  J Control Release       Date:  2013-05-25       Impact factor: 9.776

10.  Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells.

Authors:  Lisa A Gurski; Amit K Jha; Chu Zhang; Xinqiao Jia; Mary C Farach-Carson
Journal:  Biomaterials       Date:  2009-08-19       Impact factor: 12.479
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.